EyePoint Pharmaceuticals (NASDAQ:EYPT) PT Raised to $27.00

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) had its price target raised by research analysts at HC Wainwright from $25.00 to $27.00 in a report issued on Friday, The Fly reports. HC Wainwright’s price target suggests a potential upside of 315.38% from the stock’s previous close.

A number of other brokerages have also recently weighed in on EYPT. Robert W. Baird assumed coverage on EyePoint Pharmaceuticals in a report on Thursday, April 20th. They set an “outperform” rating and a $33.00 price objective on the stock. Chardan Capital raised their price objective on EyePoint Pharmaceuticals from $21.00 to $22.00 in a report on Thursday. Finally, StockNews.com raised EyePoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.50.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT opened at $6.50 on Friday. The stock’s 50-day simple moving average is $4.71 and its 200 day simple moving average is $4.07. The stock has a market capitalization of $222.95 million, a price-to-earnings ratio of -2.38 and a beta of 1.12. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.21 and a current ratio of 5.36. EyePoint Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $11.44.

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) last released its quarterly earnings results on Thursday, March 2nd. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.02. EyePoint Pharmaceuticals had a negative return on equity of 70.70% and a negative net margin of 257.44%. The firm had revenue of $10.53 million for the quarter, compared to analysts’ expectations of $9.71 million. Research analysts forecast that EyePoint Pharmaceuticals will post -2.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EYPT. Barclays PLC raised its stake in shares of EyePoint Pharmaceuticals by 533.4% in the fourth quarter. Barclays PLC now owns 7,005 shares of the company’s stock worth $25,000 after purchasing an additional 5,899 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of EyePoint Pharmaceuticals in the fourth quarter worth $36,000. Tower Research Capital LLC TRC raised its stake in shares of EyePoint Pharmaceuticals by 99.3% in the third quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $37,000 after purchasing an additional 2,294 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of EyePoint Pharmaceuticals by 46.6% in the second quarter. Cubist Systematic Strategies LLC now owns 6,600 shares of the company’s stock worth $52,000 after purchasing an additional 2,099 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in shares of EyePoint Pharmaceuticals in the first quarter worth $57,000. Hedge funds and other institutional investors own 88.27% of the company’s stock.

About EyePoint Pharmaceuticals

(Get Rating)

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.